Skip to main content
Erschienen in: Clinical and Experimental Nephrology 3/2015

01.06.2015 | Original Article

Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats

verfasst von: Yoshihito Tashiro, Kenji Yogo, Kenichi Serizawa, Koichi Endo

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypertension is a risk factor common to both chronic kidney disease and cardiovascular disease. Nicorandil is widely used for the treatment of angina. We investigated the benefits of nicorandil with respect to renal dysfunction in Dahl salt-sensitive hypertensive (DS) rats.

Method

DS rats were fed a high-salt (HS) diet and nicorandil was administered via the drinking water. Blood pressure and renal function were measured for 4 weeks after starting the rats on the HS diet.

Results

In rats fed the HS diet, renal dysfunction was manifested by an increase in urinary protein and N-acetyl-β-d-glucosaminidase excretion. Nicorandil ameliorated renal function with a concomitant reduction in urinary 8-hydroxy-2′-deoxyguanosine and an increase in urinary NOx. Significant upregulation of endothelial nitric oxide synthase (eNOS) expression and an increase in the eNOS dimer/monomer ratio (reduction of eNOS uncoupling) was demonstrated in glomeruli following nicorandil treatment. The blood pressure of DS rats was increased by salt loading; however, no significant change in blood pressure was observed with nicorandil treatment.

Conclusion

In DS rats fed a HS diet, nicorandil prevented the development of renal dysfunction, which was accompanied by an increase in eNOS expression in the kidneys.
Literatur
1.
Zurück zum Zitat Hayata M, Kakizoe Y, Uchimura K, Morinaga J, Yamazoe R, Mizumoto T, et al. Effect of a serine protease inhibitor on the progression of chronic renal failure. Am J Physiol Renal Physiol. 2012;303:F1126–35.PubMedCrossRef Hayata M, Kakizoe Y, Uchimura K, Morinaga J, Yamazoe R, Mizumoto T, et al. Effect of a serine protease inhibitor on the progression of chronic renal failure. Am J Physiol Renal Physiol. 2012;303:F1126–35.PubMedCrossRef
2.
Zurück zum Zitat Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37:444–8.PubMedCrossRef Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37:444–8.PubMedCrossRef
3.
Zurück zum Zitat Westermann D, Riad A, Richter U, Jäger S, Savvatis K, Schuchardt M, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. 2009;104:499–509.PubMedCrossRef Westermann D, Riad A, Richter U, Jäger S, Savvatis K, Schuchardt M, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. 2009;104:499–509.PubMedCrossRef
4.
Zurück zum Zitat Satoh M, Haruna Y, Fujimoto S, Sasaki T, Kashihara N. Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats. Hypertens Res. 2010;33:135–42.PubMedCrossRef Satoh M, Haruna Y, Fujimoto S, Sasaki T, Kashihara N. Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats. Hypertens Res. 2010;33:135–42.PubMedCrossRef
6.
Zurück zum Zitat Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther. 2007;29:110–22.PubMedCrossRef Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther. 2007;29:110–22.PubMedCrossRef
7.
Zurück zum Zitat Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia. Nephron Clin Pract. 2009;111:c212–21.PubMedCrossRef Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia. Nephron Clin Pract. 2009;111:c212–21.PubMedCrossRef
8.
Zurück zum Zitat Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Imai R, et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2009;54:307–17.PubMedCrossRef Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Imai R, et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2009;54:307–17.PubMedCrossRef
9.
Zurück zum Zitat Horinaka S, Kobayashi N, Yagi H, Mori Y, Matsuoka H. Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertensive rats with congestive heart failure. J Cardiovasc Pharmacol. 2006;47:629–35.PubMedCrossRef Horinaka S, Kobayashi N, Yagi H, Mori Y, Matsuoka H. Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertensive rats with congestive heart failure. J Cardiovasc Pharmacol. 2006;47:629–35.PubMedCrossRef
10.
Zurück zum Zitat Felder RA, Blecher M, Eisner GM, Jose PA. Cortical tubular and glomerular dopamine receptors in the rat kidney. Am J Physiol. 1984;246:F557–68.PubMed Felder RA, Blecher M, Eisner GM, Jose PA. Cortical tubular and glomerular dopamine receptors in the rat kidney. Am J Physiol. 1984;246:F557–68.PubMed
11.
Zurück zum Zitat Serizawa K, Yogo K, Tashiro Y, Koike N, Aizawa K, Hirata M, et al. Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats. Pharmacology. 2013;91:92–103.PubMedCrossRef Serizawa K, Yogo K, Tashiro Y, Koike N, Aizawa K, Hirata M, et al. Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats. Pharmacology. 2013;91:92–103.PubMedCrossRef
12.
Zurück zum Zitat Shimizu S, Saito M, Kinoshita Y, Ohmasa F, Dimitriadis F, Shomori K, et al. Nicorandil ameliorates ischaemia–reperfusion injury in the rat kidney. Br J Pharmacol. 2011;163:272–82.PubMedCentralPubMedCrossRef Shimizu S, Saito M, Kinoshita Y, Ohmasa F, Dimitriadis F, Shomori K, et al. Nicorandil ameliorates ischaemia–reperfusion injury in the rat kidney. Br J Pharmacol. 2011;163:272–82.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, et al. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol Renal Physiol. 2012;302:F1151–60.PubMedCentralPubMedCrossRef Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, et al. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol Renal Physiol. 2012;302:F1151–60.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, et al. Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol Renal Physiol. 2012;303:F339–49.PubMedCrossRef Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, et al. Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol Renal Physiol. 2012;303:F339–49.PubMedCrossRef
15.
Zurück zum Zitat Sudo H, Hirata M, Kanada H, Yorozu K, Tashiro Y, Serizawa K, et al. Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors. J Pharmacol Sci. 2009;111:53–9.PubMedCrossRef Sudo H, Hirata M, Kanada H, Yorozu K, Tashiro Y, Serizawa K, et al. Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors. J Pharmacol Sci. 2009;111:53–9.PubMedCrossRef
16.
Zurück zum Zitat Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am J Pathol. 2007;170:87–99.PubMedCentralPubMedCrossRef Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am J Pathol. 2007;170:87–99.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF. Dietary supplementation with l-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol. 1994;4:1690–4.PubMed Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF. Dietary supplementation with l-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol. 1994;4:1690–4.PubMed
18.
Zurück zum Zitat Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53–9.PubMedCentralPubMedCrossRef Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53–9.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Serizawa K, Yogo K, Aizawa K, Tashiro Y, Takahari Y, Sekine K, et al. Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress. J Pharmacol Sci. 2012;119:349–58.PubMedCrossRef Serizawa K, Yogo K, Aizawa K, Tashiro Y, Takahari Y, Sekine K, et al. Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress. J Pharmacol Sci. 2012;119:349–58.PubMedCrossRef
20.
Zurück zum Zitat Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011;10:105.PubMedCentralPubMedCrossRef Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011;10:105.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens. 2006;24:2263–70.PubMedCrossRef Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens. 2006;24:2263–70.PubMedCrossRef
22.
Zurück zum Zitat Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–8.PubMedCrossRef Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–8.PubMedCrossRef
23.
Zurück zum Zitat Lee TM, Chang NC. Effect of nicorandil on proteinuria in well controlled hypertensive patients. J Hypertens. 2009;27:618–25.PubMedCrossRef Lee TM, Chang NC. Effect of nicorandil on proteinuria in well controlled hypertensive patients. J Hypertens. 2009;27:618–25.PubMedCrossRef
Metadaten
Titel
Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats
verfasst von
Yoshihito Tashiro
Kenji Yogo
Kenichi Serizawa
Koichi Endo
Publikationsdatum
01.06.2015
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 3/2015
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0998-6

Weitere Artikel der Ausgabe 3/2015

Clinical and Experimental Nephrology 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.